虽然FIDELIO-DKD事后分析发现,在平均随访2.6年研究期间,两组患者均持续存在血钾水平>5.5mmol/L的风险,且Finerenone组累积发生率高于安慰剂组(21.4% vs 9.2%),但研究期间遵循如下血钾管理策略后(如图3),有效地控制了因高钾血症导致...
December 17, 2020 1 min read Save FIDELIO-DKDAdd topic to email alerts CV outcomes of finerenone (Bayer) vs. placebo in patients with type 2 diabetes and chronic kidney disease.Read more from Trial Scorecards View all May 18, 2023 1 min read Save UK Mini Mitral May 18, 2023 1 ...
hyperkalemiamineralocorticoid receptor antagonistBackground Finerenone reduced risk of cardiorenal outcomes in patients with CKD and type 2 diabetes in the FIDELIO-DKD trial. We report incidences and risk factors for hyperkalemia with finerenone and placebo in FIDELIO-DKD.Methods This post hoc safety ...
FIDELIO-DKD is a large trial looking at a non-steroidal mineralocorticoid receptor antagonist or MRA, that is called finerenone compared against placebo in 5734 patients with type 2 diabetes, and CKD with estimated glomerular filtration rate (EGFR) between 25 and 75. The primary endpoint of this...
Aims:This prespecified analysis of the FIDELIO-DKD trial compared the effects of finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) by history of heart failure (HF). Methods an...
in stage 1 to 4 CKD patients with type 2 diabetes (T2D) (FIDELIO-DKD and FIGARO-DKD trials)Aim: To test whether finerenone improves renal and/or ... Ixchel Lima Posada,Yohan STEPHAN,Matthieu Soulié,... - Hypertension 被引量: 0发表: 2023年 加载更多来源...
This analysis investigated how differences in trial design between FIDELIO-DKD and CREDENCE influence the treatment effects of the two drugs. Methods This was a post hoc analysis of FIDELIO-DKD that included patients meeting the CKD inclusion criteria of the CREDENCE study (urine albumin-to-...
POS-829 Incidence and predictors of hyperkalaemia in patients with CKD and T2D in the FIDELIO-DKD trialdoi:10.1016/j.ekir.2021.03.867R. AgarwalA. JosephP. RossingB. PittG. Bakris LKidney International Reports
This study aims to assess if these criteria similarly apply to the Canadian population.We applied the FIDELIO and FIGARO trial criteria to Canadians with T2D in a community endocrinology setting, who were already optimized for renal risk with RAAS and SGLT2 therapy.Of 369 individuals with T2D ...
eligibility criteria for inclusion in the FIDELIO-DKD and FIGARO-DKD trials.Among 343,037 T2D patients involved in the analysis, 5.4% met the eligibility criteria of the FIDELIO-DKD study (13.3% if we consider the population with fundus data) and 22.3% met those of the FIGARO-DKD trial. Ov...